Shire Pharmaceuticals LLC and subsidiaries of the Ireland-based drug maker have entered into a “landmark” settlement with the U.S. government, agreeing to pay $350 million to resolve a series of whistleblower lawsuits alleging the company used kickbacks and unlawful tactics to boost sales of its Dermagraft treatment for diabetic foot ulcers. According to Benjamin Mizer, principal deputy assistant attorney general and head of the Justice Department’s civil division, the settlement is the largest False Claims Act recovery in the U.S. in a kickback case involving a medical device. Allegations resolved by the settlement were brought in six lawsuits filed under the qui tam, ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.